Merck KGaA v. Hopewell Pharma Ventures, Inc.

Merck KGaA v. Hopewell Pharma Ventures, Inc. was a significant patent infringement litigation centered on pharmaceutical compounds, initiated by global science and technology company Merck KGaA against Hopewell Pharma Ventures, Inc. Merck KGaA, a diversified German multinational, operates in healthcare, life science, and electronics, and is the developer and manufacturer of original drugs such as MAVENCLAD®. Defendant Hopewell Pharma Ventures, Inc., founded in 2021, is a U.S.-based generic pharmaceutical company that strategically focuses on bringing complex, limited-competition generic drugs to market, often navigating intellectual property hurdles through validity challenges or non-infringement strategies. The dispute arose from Hopewell's filing of Abbreviated New Drug Application (ANDA) No. 215547 with the FDA, seeking approval for a generic version of Merck's MAVENCLAD® (cladribine 10 mg tablets), used for treating progressive forms of multiple sclerosis. Hopewell's ANDA product was represented as having the same active ingredient, dosage forms, strengths, and bioequivalence as MAVENCLAD®. The primary patent asserted in the litigation, US8377903, along with US7713947 (and initially US10849919), related to a cladribine regimen for treating multiple sclerosis, specifically detailing an oral administration with an induction period followed by a cladribine-free period.

The case was filed in the U.S. District Court for the District of Delaware (Case No. 1:22-cv-01365) before Judge Gregory Brian Williams. The District of Delaware is a prominent venue for patent litigation, particularly for pharmaceutical cases, due to its well-versed judiciary in patent law and the high number of corporations incorporated in the state, a factor amplified by the Supreme Court's TC Heartland decision. This litigation proceeded as a Hatch-Waxman action, triggered by Hopewell's ANDA filing, which automatically imposed a 30-month stay on FDA approval for Hopewell's generic product.

This case is particularly notable for its outcome: the Delaware District Court entered final judgment invalidating claims of US8377903 and US7713947 as obvious. This district court judgment was directly driven by a precedential decision from the Federal Circuit, which affirmed prior unpatentability determinations made by the Patent Trial and Appeal Board (PTAB) in inter partes reviews (IPR2023-00480 and IPR2023-00481) filed by Hopewell. The Federal Circuit's ruling (Merck Serono S.A. v. Hopewell Pharma Ventures, Inc., Nos. 2025-1210 and 2025-1211) found the patents obvious over combinations of prior art, including Bodor and Stelmasiak. The invalidation cleared the path for Hopewell's generic cladribine product to receive FDA approval, underscoring the vulnerability of pharmaceutical method and formulation patents to obviousness challenges and highlighting the strategic importance of PTAB proceedings in Hatch-Waxman litigation. The Federal Circuit's obviousness analysis in this case is anticipated to be a significant precedent for future pharmaceutical patent litigation involving similar dosing regimen claims.

Merck KGaA's patent infringement litigation against Hopewell Pharma Ventures, Inc. (Case No. 1:22-cv-01365) in the District of Delaware involved claims related to cladribine dosing regimens for treating multiple sclerosis. The case concluded with a judgment in favor of Hopewell, driven largely by successful patent challenges at the Patent Trial and Appeal Board (PTAB) and subsequent affirmation by the Federal Circuit.

Here is a chronological overview of the key legal developments and outcomes:

• Filing & Initial Pleadings:

  • 2022-10-17: Merck KGaA, along with Merck Serono SA and Ares Trading SA (collectively, "Merck"), filed a complaint against Hopewell Pharma Ventures, Inc. in the U.S. District Court for the District of Delaware. Merck alleged patent infringement arising from Hopewell's submission of Abbreviated New Drug Application (ANDA) No. 215547 to the FDA, seeking approval to market a generic version of Merck's MAVENCLAD® product before the expiration of U.S. Patent Nos. 7,713,947, 8,377,903, and 10,849,919. The filing triggered a 30-month statutory stay of FDA approval.
  • 2022-12-12: Hopewell filed its Answer to the Complaint and asserted counterclaims for declaratory judgment of invalidity of U.S. Patent Nos. 7,713,947, 8,377,903, and 10,849,919, and for unenforceability of the '919 patent.
  • December 2022: Hopewell filed a motion to dismiss, challenging patent validity and non-infringement, which the court subsequently denied.

• Pre-trial Motions of Substance:

  • January 2023: Both parties engaged in fact and expert discovery, with depositions commencing.
  • 2023-05-19: The court, through Judge Gregory B. Williams, granted a stipulation extending the time for parties to file a Proposed Order Governing Electronic Discovery to June 2, 2023.
  • 2023-12-04: The District Court ordered the consolidation of Merck's actions against Hopewell and other defendants (including Aurobindo Pharma USA Inc. and Apotex Inc.) for all purposes except trial, designating C.A. No. 22-1365 as the lead action.
  • 2024-11-27: Hopewell filed an Emergency Motion to Stay the Case pending the resolution of any appeal of IPR2023-00480 and IPR2023-00481, in which the PTAB had held claims of U.S. Patent Nos. 7,713,947 and 8,377,903 invalid as obvious.
  • 2024-12-23: The District Court granted Hopewell's Emergency Motion to Stay the Case and tolled the 30-month statutory stay of FDA approval.
  • 2025-01-16: The court subsequently imposed a global stay on Merck's actions against the remaining defendants.
  • 2025-12-04: Hopewell's Emergency Motion to Lift the Regulatory Stay, which would have allowed the FDA to grant final approval of its ANDA, was denied by the District Court.

• Claim Construction (Markman) Outcomes:

  • 2024-01-30: A Markman hearing was held, during which the court heard arguments from the parties regarding disputed terms. The matter was taken under advisement. The ultimate resolution of the case by the Federal Circuit affirming PTAB invalidity decisions effectively rendered a separate claim construction ruling by the district court less significant or moot.

• Parallel PTAB IPR Proceedings and Effect on Litigation:

  • 2023: Hopewell filed inter partes review (IPR) petitions with the Patent Trial and Appeal Board (PTAB), challenging claims of U.S. Patent Nos. 7,713,947 and 8,377,903 as obvious. Specifically, IPR2023-00480 targeted the '947 patent, and IPR2023-00481 targeted the '903 patent.
  • 2023-09-22: The PTAB instituted trial on IPR2023-00480.
  • 2024-09-18: The PTAB issued Final Written Decisions in both IPR2023-00480 and IPR2023-00481. The Board determined that Hopewell had proven by a preponderance of the evidence that the challenged claims of US7713947 (claims 36, 38, 39, and 41–46) and US8377903 (claims 17, 19, 20, and 22–27) were unpatentable as obvious over a combination of prior art references (Bodor and Stelmasiak).
  • 2025-10-30: Merck appealed the PTAB's decisions to the U.S. Court of Appeals for the Federal Circuit (Case Nos. 2025-1210 and 2025-1211). The Federal Circuit affirmed the PTAB's unpatentability determinations for both the '947 and '903 patents, holding the challenged claims unpatentable as obvious.
  • 2026-01-26: The Federal Circuit declined to reconsider its earlier decision, upholding the PTAB's rulings that Merck's patent claims were obvious.

• Final Disposition:

  • 2026-01-29: The Delaware District Court case was terminated with a final judgment. [Provided in prompt] The dispositive resolution in favor of Hopewell Pharma Ventures, Inc., invalidating claims of US8377903 (among other patents) as obvious, stemmed directly from the Federal Circuit's affirmation of the PTAB's IPR decisions, rather than a district court trial verdict.
  • No damages were awarded, and no injunctive relief was granted to Merck.

The plaintiff, Merck KGaA, was represented by a team of attorneys from Wilmer Cutler Pickering Hale & Dorr LLP and local counsel from Morris, Nichols, Arsht & Tunnell LLP.

Here is the counsel of record for the plaintiff(s):

• Jeremy A. Tigan

  • Role: Local Counsel
  • Firm: Morris, Nichols, Arsht & Tunnell LLP, Wilmington, DE
  • Note: Jeremy A. Tigan is a partner at Morris, Nichols, Arsht & Tunnell LLP, where his practice focuses on intellectual property litigation, particularly in the life sciences and technology sectors. He regularly represents clients in patent, trademark, and trade secret disputes in the District of Delaware.

• David B. Bassett

  • Role: Partner, Lead Counsel
  • Firm: Wilmer Cutler Pickering Hale & Dorr LLP, New York, NY
  • Note: Mr. Bassett is an experienced patent litigator frequently sought after by pharmaceutical and biotech clients for high-value disputes. He co-led a landmark patent infringement trial for Gilead Sciences against the US government concerning HIV-prevention drugs, where the jury found the government's patents invalid.

• Mary Pheng

  • Role: Partner, Lead Counsel
  • Firm: Wilmer Cutler Pickering Hale & Dorr LLP, New York, NY
  • Note: Mary Pheng is a partner in WilmerHale's Intellectual Property Litigation practice, focusing on patent litigation. She was listed as counsel for Merck Serono SA in an inter partes review (IPR) related to one of the patents at issue in this case (US8377903).

• Gillian T. Farrell

  • Role: Counsel, Lead Counsel
  • Firm: Wilmer Cutler Pickering Hale & Dorr LLP, New York, NY
  • Note: Ms. Farrell is a counsel in WilmerHale's Intellectual Property Litigation and Trial Practice Groups. She has represented clients in intellectual property disputes across a range of technologies, including pharmaceuticals, and was part of the legal team in the Gilead Sciences patent trial victory.

• Vinita Ferrera

  • Role: Partner, Lead Counsel
  • Firm: Wilmer Cutler Pickering Hale & Dorr LLP, Boston, MA
  • Note: Ms. Ferrera focuses her practice on complex commercial litigation with an emphasis on intellectual property disputes, including patent, trademark, and trade secret claims, across various industries such as pharmaceuticals and biotechnology. She played a significant role in the landmark Gilead Sciences patent infringement trial.

• Emily R. Whelan

  • Role: Counsel, Lead Counsel
  • Firm: Wilmer Cutler Pickering Hale & Dorr LLP, Boston, MA
  • Note: Ms. Whelan was listed as Lead Counsel for Merck Serono SA in an IPR concerning US8377903, one of the patents in this litigation. She also contributed to the WilmerHale team that achieved a patent victory for Gilead Sciences.

• Deric X. Geng

  • Role: Partner, Lead Counsel
  • Firm: Wilmer Cutler Pickering Hale & Dorr LLP, Boston, MA
  • Note: Dr. Geng is a partner with a PhD. He was part of the WilmerHale legal team that secured a landmark patent victory for Gilead Sciences against the US government.

• Wenli Gu

  • Role: Counsel, Lead Counsel
  • Firm: Wilmer Cutler Pickering Hale & Dorr LLP, Boston, MA
  • Note: Dr. Gu represents clients in intellectual property rights, particularly in the life sciences industry, and was part of the legal team for Gilead Sciences in its patent victory. She holds a PhD in Genetics.

• Asher S. McGuffin

  • Role: Counsel, Lead Counsel
  • Firm: Wilmer Cutler Pickering Hale & Dorr LLP, Boston, MA
  • Note: Mr. McGuffin specializes in patent, trade secret, and antitrust litigation, with extensive experience in high-stakes patent and trade secret trials, including in the pharmaceutical sector. He previously served as a judicial law clerk for Judge Jennifer L. Hall in the District of Delaware, a prominent patent litigation venue.

• H. Rachael Million-Perez

  • Role: Counsel, Lead Counsel
  • Firm: Wilmer Cutler Pickering Hale & Dorr LLP, Denver, CO
  • Note: Ms. Million-Perez is an intellectual property counsel who represents clients across various technical sectors, including pharmaceuticals, medical devices, and electronics, with experience in federal district courts, PTAB proceedings, and Federal Circuit appeals.

• Reid M. Whitaker

  • Role: Senior Associate, Lead Counsel
  • Firm: Wilmer Cutler Pickering Hale & Dorr LLP, Washington, D.C.
  • Note: Mr. Whitaker focuses his practice on patent litigation and complex civil litigation involving technology. He previously clerked for judges on the Federal Circuit, Third Circuit, and the District of Delaware.

• Nora N. Xu

  • Role: Counsel, Lead Counsel
  • Firm: Wilmer Cutler Pickering Hale & Dorr LLP, Washington, D.C.
  • Note: Ms. Xu focuses her practice on intellectual property litigation before federal district courts, appellate courts, and administrative agencies, representing clients in patent cases involving pharmaceuticals, biologics, and medical devices. She clerked for the Honorable Raymond Chen of the US Court of Appeals for the Federal Circuit.

Hopewell Pharma Ventures, Inc. was represented by counsel from Sterne, Kessler, Goldstein & Fox PLLC, which played a pivotal role in the successful invalidation of Merck's patents. Although specific filings for counsel of record at the District Court level were not directly accessible, Sterne Kessler's press release explicitly details their representation of Hopewell in the overarching "ongoing patent dispute" that culminated in the Federal Circuit's decision, which led to the District Court's final judgment.

The counsel identified for Hopewell Pharma Ventures, Inc. includes:

• J.C. Rozendaal
  • Role: Lead Counsel (Director)
  • Firm: Sterne, Kessler, Goldstein & Fox PLLC, Washington, D.C.
  • Note: Led the Sterne Kessler team that secured a Federal Circuit victory for Hopewell, upholding the invalidation of Merck's patents as obvious.
• Eldora Ellison, Ph.D.
  • Role: Counsel (Director)
  • Firm: Sterne, Kessler, Goldstein & Fox PLLC, Washington, D.C.
  • Note: Member of the Sterne Kessler team involved in the successful patent invalidation efforts for Hopewell.
• Olga Partington, Ph.D.
  • Role: Counsel (Director)
  • Firm: Sterne, Kessler, Goldstein & Fox PLLC, Washington, D.C.
  • Note: Member of the Sterne Kessler team for Hopewell in the patent dispute.
• Chandrika Vira
  • Role: Counsel (Director)
  • Firm: Sterne, Kessler, Goldstein & Fox PLLC, Washington, D.C.
  • Note: Contributed to Hopewell's defense strategy in the patent litigation.
• Richard Crudo
  • Role: Counsel (Director)
  • Firm: Sterne, Kessler, Goldstein & Fox PLLC, Washington, D.C.
  • Note: Part of the legal team representing Hopewell in its patent defense.
• Christina Dashe
  • Role: Counsel
  • Firm: Sterne, Kessler, Goldstein & & Fox PLLC, Washington, D.C.
  • Note: Served as counsel for Hopewell in the patent litigation.
• Tyler Liu
  • Role: Counsel
  • Firm: Sterne, Kessler, Goldstein & Fox PLLC, Washington, D.C.
  • Note: Involved as counsel for Hopewell in the patent dispute.

Additionally, while primarily noted for their involvement in the Federal Circuit appeal of the related inter partes review (IPR) decisions, the following attorneys from Schwabe, Williamson & Wyatt were also involved in the broader challenge to Merck's patents:

• Nika Aldrich
  • Role: Shareholder
  • Firm: Schwabe, Williamson & Wyatt (office location not specified in source)
  • Note: Involved in the Federal Circuit case that upheld the invalidation of Merck's patents, which was critical to the District Court outcome.
• Jason Wrubleski
  • Role: Shareholder
  • Firm: Schwabe, Williamson & Wyatt (office location not specified in source)
  • Note: Contributed to the appellate proceedings that affirmed the invalidity of Merck's patents.
• Julia Davis
  • Role: Associate
  • Firm: Schwabe, Williamson & Wyatt (office location not specified in source)
  • Note: Member of the team involved in the Federal Circuit appeal concerning the invalidation of Merck's patents.

No specific local counsel for the District of Delaware was identified in the provided search results.